GlassScriptPhysician profile
James A Rahto
NPI 1902892862
$10,743.20
in general payments reported to CMS, 2019-2025
58 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $555 · 2021: $1,360 · 2022: $2,081 · 2023: $1,780 · 2024: $1,782 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,593.03 | 2020-2025 | |
| Novo Nordisk INC | $1,152.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $914.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $895.00 | 2019-2025 | Xifaxan, Plenvu |
| Amgen INC. | $578.22 | 2019-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.81 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $399.47 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $346.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $335.86 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Merck Sharp & Dohme LLC | $302.74 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Antares Pharma, INC. | $288.18 | 2019-2025 | Xyosted |
| Abbott Laboratories | $231.55 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $220.21 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $205.03 | 2019-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $203.09 | 2019-2023 | Austedo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rahto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.